Dear Madam/Sir,
Please note MorphoSys’s financial reporting dates 2017 as follows:
March 9, 2017: Year-End 2016 Results
May 3, 2017: Publication of First Quarter Interim Statement 2017
August 3, 2017: Publication of Half-Year Report 2017
November 7, 2017: Publication of Third Quarter Interim Statement 2017
May 17, 2017: Annual General Meeting in Munich
For a direct import of the dates to your calendar, please visit our corporate website: https://www.morphosys.com/media-and-investors/morphosys-events#company-calendar
With season’s greetings and good wishes for the New Year:
www.morphosys.com/xmas-2016
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer’s disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com.
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia®, 100 billion high potentials®, Slonomics®, Lanthio Pharma® and LanthioPep® are registered trademarks of the MorphoSys Group.
